LAPIX Therapeutics Announces Completion of Enrollment in Rheumatoid Arthritis Arm of Ongoing LPX-TI641 Clinical Study
LAPIX Therapeutics, a clinical-stage biotechnology company developing a novel immunomodulatory therapy for inflammatory and immune-mediated diseases, today announced the completion of enrollment in the rheumatoid arthritis (RA) arm of its ongoing clinical study evaluating LPX-TI641, the Company's lead therapeutic candidate and a first-in-class oral TIM 3/4 agonist.
